A new study has determined that medication copayments may represent a structural barrier to medication adherence among poorer patients with pulmonary arterial hypertension (PAH).
The study, published in the Journal of the American Heart Association, noted specifically that those with high copayments had decreased adherence to prostanoids and to combination therapy.
The research team employed commercially available administrative claims data from Optum’s De-identified Clinformatics Data Mart on 4025 adults in the US with PAH to find associations between medication copayment and adherence to pulmonary vasodilator therapy. Annual household income was categorized in the Optum database as less than $40,000, $40,000 to $49,999, $50,000 to $59,999, $60,000 to $74,999, $75,000 to $99,999, and more than $100,000.
Read more about PAH therapies
Median 30-day copayments ranged from $11.05 to $60.08, depending on the specific medication.
The results showed that annual household income was not associated with better or worse medication adherence. However, higher copayments were significantly associated with poorer medication adherence to prostanoids and combined therapy with endothelin receptor antagonists and phosphodiesterase type-5 inhibitors compared with low copayments.
Schikowski E, Swabe G, Chan SY, et al. Association between copayment and adherence to medications for pulmonary arterial hypertension. J Am Heart Assoc. Published online November 12, 2022. doi:10.1161/JAHA.122.026620